CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
57.96
0.99%
Market Trading Hours* (UTC) Open now
Closes on Friday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.15
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Incyte Corp ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 58.53
Open* 58.53
1-Year Change* -13.42%
Day's Range* 57.95 - 58.53
52 wk Range 60.56-86.29
Average Volume (10 days) 1.54M
Average Volume (3 months) 37.32M
Market Cap 14.22B
P/E Ratio 38.98
Shares Outstanding 224.09M
Revenue 3.51B
EPS 1.63
Dividend (Yield %) N/A
Beta 0.69
Next Earnings Date Oct 30, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 28, 2023 58.53 -0.22 -0.37% 58.75 59.22 58.35
Sep 27, 2023 59.03 -0.16 -0.27% 59.19 59.78 58.65
Sep 26, 2023 59.19 1.02 1.75% 58.17 59.57 58.02
Sep 25, 2023 58.68 1.05 1.82% 57.63 58.77 57.43
Sep 22, 2023 58.03 -0.42 -0.72% 58.45 59.21 57.86
Sep 21, 2023 58.70 -1.35 -2.25% 60.05 60.24 58.69
Sep 20, 2023 60.29 0.49 0.82% 59.80 60.93 59.79
Sep 19, 2023 60.51 1.26 2.13% 59.25 60.77 59.23
Sep 18, 2023 59.44 -0.11 -0.18% 59.55 59.98 58.21
Sep 15, 2023 62.46 -0.54 -0.86% 63.00 63.80 62.25
Sep 14, 2023 63.39 0.57 0.91% 62.82 63.79 62.60
Sep 13, 2023 63.02 -0.96 -1.50% 63.98 64.50 62.84
Sep 12, 2023 64.15 0.15 0.23% 64.00 64.59 63.56
Sep 11, 2023 64.32 0.55 0.86% 63.77 64.77 63.58
Sep 8, 2023 63.89 0.47 0.74% 63.42 64.28 63.42
Sep 7, 2023 63.37 0.49 0.78% 62.88 63.48 62.62
Sep 6, 2023 63.12 0.09 0.14% 63.03 63.45 62.41
Sep 5, 2023 63.19 -0.79 -1.23% 63.98 65.08 63.16
Sep 1, 2023 64.61 0.04 0.06% 64.57 65.36 64.39
Aug 31, 2023 64.44 -0.63 -0.97% 65.07 65.28 64.27

Incyte Corporation Events

Time (UTC) Country Event
Monday, October 30, 2023

Time (UTC)

11:00

Country

US

Event

Q3 2023 Incyte Corp Earnings Release
Q3 2023 Incyte Corp Earnings Release

Forecast

-

Previous

-
Monday, February 5, 2024

Time (UTC)

12:00

Country

US

Event

Q4 2023 Incyte Corp Earnings Release
Q4 2023 Incyte Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3394.64 2986.27 2666.7 2158.76 1881.88
Revenue 3394.64 2986.27 2666.7 2158.76 1881.88
Cost of Revenue, Total 185.497 129.491 109.828 92.749 72.623
Gross Profit 3209.14 2856.78 2556.87 2066.01 1809.26
Total Operating Expense 2815.2 2400.49 2930.38 1756.75 1752.66
Selling/General/Admin. Expenses, Total 1002.14 739.56 516.922 468.711 434.407
Research & Development 1585.94 1458.18 2215.94 1154.11 1197.96
Depreciation / Amortization 21.5 21.5 21.5 21.5 21.5
Unusual Expense (Income) 20.122 51.76 66.186 19.682 26.173
Operating Income 579.44 585.777 -263.676 402.006 129.223
Interest Income (Expense), Net Non-Operating -90.256 -25.98 31.458 84.785 -45.636
Net Income Before Taxes 529.116 570.444 -232.218 486.791 115.347
Net Income After Taxes 340.66 948.581 -295.697 446.906 109.493
Net Income Before Extra. Items 340.66 948.581 -295.697 446.906 109.493
Net Income 340.66 948.581 -295.697 446.906 109.493
Income Available to Common Excl. Extra. Items 340.66 948.581 -295.697 446.906 109.493
Income Available to Common Incl. Extra. Items 340.66 948.581 -295.697 446.906 109.493
Dilution Adjustment
Diluted Net Income 340.66 948.581 -295.697 446.906 109.493
Diluted Weighted Average Shares 223.958 222.074 218.073 217.657 215.635
Diluted EPS Excluding Extraordinary Items 1.52109 4.27146 -1.35595 2.05326 0.50777
Diluted Normalized EPS 1.57893 4.42296 -1.15868 2.13628 0.62299
Other, Net 39.932 10.647 31.76
Total Extraordinary Items 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 954.61 808.673 926.7 823.303 911.397
Revenue 954.61 808.673 926.7 823.303 911.397
Cost of Revenue, Total 62.626 51.422 53.763 49.284 45.236
Gross Profit 891.984 757.251 872.937 774.019 866.161
Total Operating Expense 760.83 783.903 856.607 684.927 656.966
Selling/General/Admin. Expenses, Total 283.929 315.606 272.819 266.46 253.277
Research & Development 400.75 406.641 501.36 384.007 347.196
Depreciation / Amortization 5.7 5.4 5.4 5.3 5.4
Unusual Expense (Income) 7.825 4.834 23.265 -20.124 5.857
Operating Income 193.78 24.77 70.093 138.376 254.431
Interest Income (Expense), Net Non-Operating 41.156 -5.787 -16.115 -1.301 -25.575
Other, Net 42.668 32.873 26.637 11.513 0.522
Net Income Before Taxes 277.604 51.856 80.615 148.588 229.378
Net Income After Taxes 203.548 21.703 28.461 112.775 161.432
Net Income Before Extra. Items 203.548 21.703 28.461 112.775 161.432
Net Income 203.548 21.703 28.461 112.775 161.432
Income Available to Common Excl. Extra. Items 203.548 21.703 28.461 112.775 161.432
Income Available to Common Incl. Extra. Items 203.548 21.703 28.461 112.775 161.432
Diluted Net Income 203.548 21.703 28.461 112.775 161.432
Diluted Weighted Average Shares 225.649 225.589 224.954 224.175 223.661
Diluted EPS Excluding Extraordinary Items 0.90206 0.09621 0.12652 0.50307 0.72177
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.92748 0.10517 0.19374 0.43493 0.7402
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 4092.85 3118.67 2359.89 2481.49 1832.25
Cash and Short Term Investments 3238.97 2348.19 1801.38 2117.55 1438.32
Cash & Equivalents 2951.42 2057.44 1513.01 1832.68 1163.98
Short Term Investments 287.543 290.752 288.369 284.87 274.343
Total Receivables, Net 644.879 616.3 481.994 308.809 307.598
Accounts Receivable - Trade, Net 644.879 616.3 481.794 308.409 306.898
Total Inventory 41.995 27.904 16.425 11.4 6.967
Prepaid Expenses 167.011 126.278 60.098 43.725 79.366
Other Current Assets, Total
Total Assets 5840.98 4933.35 3560.92 3426.75 2645.76
Property/Plant/Equipment, Total - Net 765.608 751.468 588.076 406.625 319.751
Property/Plant/Equipment, Total - Gross 978.422 927.188 732.45 528.495 422.982
Accumulated Depreciation, Total -212.814 -175.72 -144.374 -121.87 -103.231
Goodwill, Net 155.593 155.593 155.593 155.593 155.593
Intangibles, Net 129.219 150.755 172.291 193.828 215.364
Long Term Investments 133.676 221.266 222.301 133.657 99.199
Other Long Term Assets, Total 564.038 535.596 62.763 55.559 23.601
Total Current Liabilities 1157.08 854.308 631.195 513.34 425.277
Accounts Payable 277.546 172.11 98.767 83.647 103.827
Accrued Expenses 575.634 460.262 370.729 274.741 191.572
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 300.718 219.301 159.415 135.988 111.182
Total Liabilities 1470.86 1163.35 949.65 828.344 719.795
Total Long Term Debt 30.083 31.632 32.573 31.918 17.434
Long Term Debt 0 0 17.434
Other Liabilities, Total 283.705 277.408 285.882 283.086 277.084
Total Equity 4370.12 3770 2611.27 2598.41 1925.97
Common Stock 0.223 0.221 0.219 0.216 0.213
Additional Paid-In Capital 4792.04 4567.11 4352.86 4044.49 3813.68
Retained Earnings (Accumulated Deficit) -437.214 -777.874 -1726.45 -1430.76 -1877.76
Other Equity, Total 15.069 -19.454 -15.36 -15.542 -10.165
Total Liabilities & Shareholders’ Equity 5840.98 4933.35 3560.92 3426.75 2645.76
Total Common Shares Outstanding 222.747 221.084 219.489 216.178 213.275
Current Port. of LT Debt/Capital Leases 3.179 2.635 2.284 18.964 18.696
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Capital Lease Obligations 30.083 31.632 32.573 31.918
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 3971.63 4092.85 3821.11 3625.84 3288.09
Cash and Short Term Investments 3112.71 3238.97 2977.12 2722.43 2544.16
Cash & Equivalents 2821.05 2951.42 2690.62 2435.38 2256.76
Short Term Investments 291.661 287.543 286.5 287.044 287.401
Total Receivables, Net 623.788 644.879 618.188 682.968 562.344
Accounts Receivable - Trade, Net 623.788 644.879 618.188 682.968 562.344
Total Inventory 40.876 41.995 45.869 54.502 35.457
Prepaid Expenses 194.257 167.011 179.932 165.95 146.13
Total Assets 5797.62 5840.98 5510.21 5319.04 5054.22
Property/Plant/Equipment, Total - Net 767.55 765.608 742.412 748.677 756.609
Property/Plant/Equipment, Total - Gross 993.226 978.422 944.392 940.535 942.42
Accumulated Depreciation, Total -225.676 -212.814 -201.98 -191.858 -185.811
Goodwill, Net 155.593 155.593 155.593 155.593 155.593
Intangibles, Net 140.658 129.219 134.603 139.987 145.371
Long Term Investments 128.313 133.676 149.124 149.784 174.681
Other Long Term Assets, Total 633.876 564.038 507.371 499.149 533.876
Total Current Liabilities 1006.11 1157.08 1006.6 926.674 886.163
Accounts Payable 55.633 277.546 163.175 194.77 152.547
Accrued Expenses 559.485 575.634 555.857 493.019 455.656
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 3.149 3.179 3.112 3.036 2.796
Other Current Liabilities, Total 387.844 300.718 284.452 235.849 275.164
Total Liabilities 1335.06 1470.86 1283.56 1233.97 1191.15
Total Long Term Debt 29.699 30.083 30.476 31.157 31.385
Capital Lease Obligations 29.699 30.083 30.476 31.157 31.385
Other Liabilities, Total 299.245 283.705 246.491 276.143 273.601
Total Equity 4462.57 4370.12 4226.65 4085.06 3863.07
Common Stock 0.223 0.223 0.222 0.222 0.221
Additional Paid-In Capital 4856.91 4792.04 4721.17 4688.98 4625.78
Retained Earnings (Accumulated Deficit) -415.511 -437.214 -465.675 -578.45 -739.882
Other Equity, Total 20.942 15.069 -29.062 -25.696 -23.047
Total Liabilities & Shareholders’ Equity 5797.62 5840.98 5510.21 5319.04 5054.22
Total Common Shares Outstanding 223.062 222.747 222.455 221.875 221.41
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 340.66 948.581 -295.697 446.906 109.493
Cash From Operating Activities 969.941 749.488 -124.599 710.656 336.227
Cash From Operating Activities 67.855 57.844 51.807 54.533 54.969
Deferred Taxes 57.091 -465.604 -0.35 -0.377 -0.459
Non-Cash Items 305.525 223.236 191.382 152.299 218.763
Cash Taxes Paid 136.242 67.731 70.712 33.553 5.417
Cash Interest Paid 0.396 0.194 0.239 0.268
Changes in Working Capital 198.81 -14.569 -71.741 57.295 -46.539
Cash From Investing Activities -78.542 -207.699 -269.001 -87.454 -86.423
Capital Expenditures -77.833 -181.006 -187.379 -78.064 -73.483
Other Investing Cash Flow Items, Total -0.709 -26.693 -81.622 -9.39 -12.94
Cash From Financing Activities -0.794 6.176 71.709 45.711 14.657
Financing Cash Flow Items -59.047 -50.033 -37.76 -16.766 -15.285
Issuance (Retirement) of Stock, Net 61.115 58.626 110.305 63.299 29.942
Issuance (Retirement) of Debt, Net -2.862 -2.417 -0.836 -0.822 0
Foreign Exchange Effects 3.355 -3.57 2.949 -0.192 0.091
Net Change in Cash 893.96 544.395 -318.942 668.721 264.552
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 21.703 340.66 312.199 199.424 37.992
Cash From Operating Activities -105.603 969.941 686.279 389.898 215.741
Cash From Operating Activities 19.211 67.855 49.637 32.945 16.438
Non-Cash Items 62.242 305.525 210.782 179.981 98.899
Cash Taxes Paid 7.107 136.242 116.537 76.464 3.472
Changes in Working Capital -186.596 198.81 73.229 -54.927 60.306
Cash From Investing Activities -28.559 -78.542 -57.63 -29.228 -16.748
Capital Expenditures -11.906 -77.833 -56.56 -28.749 -17.006
Other Investing Cash Flow Items, Total -16.653 -0.709 -1.07 -0.479 0.258
Cash From Financing Activities 4.009 -0.794 1.686 15.997 0.096
Financing Cash Flow Items -9.177 -59.047 -39.197 -20.327 -15.634
Issuance (Retirement) of Stock, Net 13.988 61.115 42.989 37.692 16.398
Issuance (Retirement) of Debt, Net -0.802 -2.862 -2.106 -1.368 -0.668
Foreign Exchange Effects -0.199 3.355 2.728 1.198 0.21
Net Change in Cash -130.352 893.96 633.063 377.865 199.299
Deferred Taxes -22.163 57.091 40.432 32.475 2.106
Cash Interest Paid
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Baker Bros. Advisors LP Hedge Fund 16.1446 36178056 2656 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.7209 21783416 116771 2023-06-30 LOW
Dodge & Cox Investment Advisor/Hedge Fund 8.6029 19277960 -54350 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 7.0749 15853966 2049984 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.3958 9850455 527398 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 2.1546 4828189 -774244 2023-06-30 HIGH
Two Sigma Investments, LP Hedge Fund 1.8732 4197574 2411239 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8196 4077490 115748 2023-06-30 LOW
Invesco Capital Management LLC Investment Advisor 1.5134 3391414 -117914 2023-06-30 LOW
Goldman Sachs Asset Management, L.P. Investment Advisor 1.1899 2666339 517858 2023-06-30 LOW
Bellevue Asset Management AG Investment Advisor 1.1785 2640765 -199735 2023-06-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.9899 2218172 461827 2023-06-30 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 0.9416 2110055 -106086 2023-06-30 LOW
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 0.8597 1926547 103516 2023-06-30 HIGH
Citadel Advisors LLC Hedge Fund 0.8155 1827413 1793088 2023-06-30 LOW
D. E. Shaw & Co., L.P. Hedge Fund 0.8057 1805514 931571 2023-06-30 HIGH
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.7987 1789723 238045 2023-06-30 LOW
Armistice Capital LLC Hedge Fund 0.7925 1776000 -96000 2023-06-30 HIGH
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.7747 1735994 223560 2023-06-30 LOW
Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.7649 1713953 290233 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Incyte Company profile

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares

Industry: Biopharmaceuticals

1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

Oil - Crude

91.00 Price
-0.630% 1D Chg, %
Long position overnight fee 0.0745%
Short position overnight fee -0.0965%
Overnight fee time 21:00 (UTC)
Spread 0.030

US100

14,806.20 Price
+0.320% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

26,920.00 Price
-0.920% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

XRP/USD

0.54 Price
+4.460% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading